Oncology Archives - Page 2 of 2 - Sagimet Biosciences

Graviton

0

Oncology

03/02/2016

Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

(Abstract #1022 and Short Presentation at Keystone Symposium, “New Frontiers in Understanding Tumor Metabolism” February 21-25, 2016, Banff, Alberta, Canada)

FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640

(Poster Presentation at AACR-NCI-EORTC meeting on Sunday Nov 8, 2015)

Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

(Poster presented at AACR-NCI-EORTC Meeting on Saturday, Nov 7, 2015)

Oncology

Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement

FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640

Biomarker Analyses from Dose Escalation Phase of FASN Inhibitor TVB-2640 Phase 1 Study Shows Target Engagement in Solid Tumor Patients

Site Map

Contact Us